Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC) - Sorafenib and Doxorubicin in Advanced HCC

All Ireland Co-operative Oncology Research Group (ICORG)0 个研究点目标入组 480 人开始时间: 2013年6月14日最近更新: 2015年10月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 480

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Patients must have pathologically or cytologically proven hepatocelluar carcinoma. Known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed.
•2. Patients must have locally advanced or metastatic disease. Locally advanced disease is defined as disease deemed to be unresectable or non-eligible for transplant without distant metastases.
•3. Patients must have Measurable Disease.
•Lesions must be accurately measurable in at least one dimension (longest diameter to be recorded) as =2 cm with conventional techniques or as =1 cm with spiral CT scan.
•4. Age: = 18 years of age
•5. ECOG Performance Status: 0-2
•6. Required Initial Laboratory Values:
•Granulocytes =1,500/µL
•Hemoglobin =8.5 g/dL*
•Platelets =75,000/µL
•Creatinine =1.5 x ULN (or Creatinine Clearance calculated =60 cc/minute)
•Child-Pugh score A (Appendix II)**
•Bilirubin=3 mg/dL
•ALT and AST =5 x ULN
•PT-INR =1.7
•Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.
•* Patients with recent or ongoing gastrointestinal bleed may not be transfused to reach the entry hemoglobin of 8.5 g/dL. Physicians should ensure patients requiring transfusion prior to registration do not have an occult or clinically apparent gastrointestinal bleed.
•**Patients must have a Child-Pugh score of A and meet all laboratory value requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 180
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 300

排除标准

•1. No prior adjuvant sorafenib or other Raf/VEGF inhibitors. Other prior adjuvant therapy is allowed if completed >6 months prior to registration with documented recurrence of HCC.
•2. Patients may have been treated with loco regional therapies provided that they either have:
•a target lesion that has not been subjected to local therapy or
•the target lesion(s) within the field of the local therapy has shown an increase of = 20% in the size since last treatment.
•Such therapy must be completed at least 4 weeks prior to registration. Patients that have received palliative radiation therapy to the bone need not wait 4 weeks to begin protocol therapy.
•Prior therapies allowed include the following:
•bland embolization, radiation, radioactive microspheres, etc
•chemoembolization using any chemotherapy (except, see D”, below)
•chemoembolization drug-eluting beads using doxorubicin
•prior therapy with chemoembolization using doxorubicin in the non drug eluting beads form is NOT allowed.
•3. No prior systemic therapy for metastatic disease.
•4. No prior exposure to systemic doxorubicin administered intravenously.
•5. Antiviral treatment is allowed, however interferon therapy must be stopped at least 4 weeks prior to registration.
•6. Allografts are not allowed: No prior history of any allograft, including but not limited to liver and bone marrow transplants.
•7. Patients must have completed any major surgery =4 weeks from registration.
•8. Concomitant treatment with Rifampin or St John’s Wort is not allowed. Patients should discontinue these drugs at least 4 weeks prior to registration.
•9. No known CNS tumors including brain metastases.
•10. No clinically significant gastrointestinal bleeding events requiring intervention, transfusion, or admission to hospital within 30 days prior to registration.
•11. Patients with a history of hypertension should be well controlled (< 140/90 mmHg) on a regimen of anti-hypertensive therapy.
•12. Significant history of cardiac disease is not allowed:
•Congestive heart failure > Class II New York Heart Assocation (NYHA)
•Myocardial infarction within 6 months prior to registration
•Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
•Serious myocardial dysfunction, defined as scintigraphically (MUGA, myocardial scintigram) determined absolute left ventricular ejection fraction (LVEF) below 45% or an LVEF below the normal limit at the individual institution.
•13. No history of bleeding diathesis.
•14. Patients receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV) are excluded from the study because of possible pharmacokinetic interactions with sorafenib.
•15. The effects of sorafenib on the developing fetus at the recommended therapeutic dose are unknown and may be teratogenic. Thus, women who are pregnant should not go on study. Women should not breastfeed while participating in this study.

研究者

发起方

All Ireland Co-operative Oncology Research Group (ICORG)

相似试验

已完成

3 期

NCT01015833National Cancer Institute (NCI)356

招募中

3 期

Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinomaHepatocellular carcinoma

JPRN-jRCT1031210167eno Makoto164

尚未招募

不适用

Phase I dose escalation study with sorafenib in combination with sirolimus in patients with solid tumor.malignant solid tumors10027655

NL-OMON30326niversitair Medisch Centrum Sint Radboud18

进行中（未招募）

1 期

A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864

EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159

Unknown

2 期

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II TrialLiver Carcinoma

NCT01272557PD Dr. med. Matthias Dollinger170